Sign inJoin waitlistJoin the waitlist

Meenakshi Hegde

Associate Professor, Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine · Baylor College of Medicine

Credentials: · · · ·

History

Baylor College of Medicine
Present

University of Illinois College of Medicine at Chicago
Pediatrics

Research

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Journal of Clinical Oncology · 2015 · 855 citations
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
JAMA Oncology · 2017 · 747 citations
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Journal of Clinical Investigation · 2016 · First of 21 authors · 595 citations

Nabil Ahmed
34 papers
Stephen Gottschalk
15 papers
Helen Heslop
13 papers
Malcolm Brenner
11 papers
John Hicks
8 papers
Kevin Bielamowicz
8 papers · 3 as a fellow
Shoba Navai
8 papers · 1 as a fellow
Bilal Omer
7 papers
Daniel Landi
7 papers · 5 as a fellow
Jordan Orange
7 papers
AA
Aidin Ashoori
5 papers
AG
Alexia Ghazi
5 papers · 3 as a resident

Grants

Modulating the PD-1/PD-L1 Checkpoint to Promote Antitumor Activity of HER2 CAR T Cells in Patients with Sarcoma
National Cancer Institute · R01
Contact PI · $2.6M · Baylor College of Medicine
2023–2028

Clinical trials

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Principal investigator · Recruiting · Phase 1
Baylor College of Medicine
2023–2040
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Principal investigator · Recruiting · Phase 1
Baylor College of Medicine
2021–2043
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Principal investigator · Active not recruiting · Phase 1
Baylor College of Medicine
2016–2037
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
Study chair · Active not recruiting · Phase 1
Children's Oncology Group
2022–2033